Caraway Tea Company

Caraway Therapeutics is a preclinical-stage biopharmaceutical company specializing in the development of small molecule therapeutics that enhance cellular clearance pathways. The company's research focuses on modulating lysosomal function and autophagy to treat neurodegenerative diseases and rare genetic disorders, including Parkinson's disease and amyotrophic lateral sclerosis (ALS). By targeting proteins such as TRPML1 and TMEM175, Caraway aims to restore the cell's ability to degrade toxic aggregates and maintain homeostasis. Originally known as Rheostat Therapeutics, the company was acquired by Merck & Co. (MSD) in November 2023 for a total potential consideration of up to 610 million dollars. This acquisition integrated Caraway's innovative lysosomal biology platform into Merck's broader neuroscience discovery efforts.